AMETHYST RADIOTERAPIA ITALIA

What AMETHYST RADIOTERAPIA ITALIA does

Amethyst Radioterapia Italia is the Italian operating entity of Stingray Healthcare Group (the pan-European platform formed by the November 2025 merger of Amethyst Healthcare and Stingray Healthcare Group, controlled by Fremman Capital). The Italian subsidiary, with its first centre on the Italian Peninsula opening in Rome in May 2017 through a partnership with the Fatebenefratelli order and an additional presence at the Azienda Ospedaliera Regionale San Carlo in Potenza, delivers radiotherapy, radiosurgery, brachytherapy, chemotherapy, and supportive oncology care to cancer patients under a multidisciplinary team model. Within the broader group, Amethyst Radioterapia Italia is one of 30+ centres spanning eight European countries (UK, France, Germany, Italy, Poland, Austria, Portugal, Romania), collectively treating more than 50,000 patients and delivering approximately 35,000 radiotherapy treatments annually.

The clinical platform is built around linear accelerators (LINACs) such as the Elekta Versa HD with Agility multi-leaf collimator for VMAT/IMRT delivery, supplemented by Gamma Knife systems (Leksell) at UK sites, the only dedicated CyberKnife in Portugal, and brachytherapy suites. The group is layering AI-assisted radiotherapy planning and AI-driven tumour contouring (analysing MRI scans to map tumour geometry) onto this hardware base to improve precision, reduce planning variability, and shorten treatment courses — for example, breast cancer radiotherapy is reported to have shifted from approximately 30 sessions over six weeks to 5–20 sessions over one to four weeks. The platform's AI/ML layer appears to be an integrated clinical feature rather than an independently commercialised product.

The business model combines direct patient service revenue (radiotherapy and oncology treatments delivered to individuals and reimbursed through mixed public/private channels) with managed-services revenue generated through long-term institutional partnerships and public-private partnerships (PPPs) with public hospitals and national health systems, plus a distinct physician-partnership model in which independent oncology practice owners retain clinical independence while accessing the European network's capital, technology, and shared expertise. Go-to-market is enterprise/relationship-led rather than transactional — relying on senior clinical engagement with hospital management, regulatory familiarity across multiple European jurisdictions, and earned-media channels (Healthcare Business International, RAD Magazine, conference participation at events such as ESTRO). Combined group revenue exceeds €200 million, supported by €300 million in debt financing from Ares Management, with Fremman Capital providing equity sponsorship for further consolidation across Europe.

Name

AMETHYST RADIOTERAPIA ITALIA

Legal name

Amethyst Radioterapia Italia

Website

https://amethysthealthcare.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Amethyst Radioterapia Italia is an Italian subsidiary of Stingray Healthcare Group, Europe's largest independent cancer care platform, delivering radiotherapy, radiosurgery, brachytherapy, and chemotherapy across 30+ centres in eight European countries via institutional and physician partnerships.

Ownership category

akta.pro rank

Product category

Radiotherapy and Cancer Care Services

NAICS

Ambulatory Health Care Services (621), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Diagnostic Imaging Centers (621512)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Radiotherapy services
• Cancer care treatments
• Stereotactic radiosurgery
• Oncology center operations
• Brachytherapy treatments

Headquarters

HQ city

Potenza

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Radiotherapy and Oncology Treatment Services: Direct patient care revenue from radiotherapy, radiosurgery, brachytherapy, chemotherapy and supportive therapies delivered to cancer patients at network centres across Europe.
2. Institutional Partnership Fees: Revenue generated through partnerships with hospitals, health authorities, and national health systems, including public-private partnerships (PPPs) where the group operates on behalf of public facilities to increase treatment capacity and modernise equipment.
3. Medical Practice Partnership Model: Partnership model with physicians and cancer centre directors — long-term investments supporting development of centres while the group generates returns through network scale and shared expertise.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Amethyst Radioterapia Italia operates a network of radiotherapy and oncology treatment centers in Italy, delivering precision external beam radiotherapy, stereotactic radiosurgery, brachytherapy, chemotherapy, and supportive oncology services. The Italian entity is part of the pan-European Stingray/Amethyst network, treating cancer patients through partnerships with leading public hospitals and healthcare institutions, while leveraging AI-assisted treatment planning and advanced platforms such as Gamma Knife and CyberKnife.

Product overview

Amethyst Healthcare Group operates as a pan-European radiotherapy and cancer care platform consisting of multiple regional treatment centers across Europe. The company's portfolio includes radiotherapy services (external beam radiation therapy using linear accelerators), brachytherapy (internal radiation therapy), chemotherapy, and stereotactic radiosurgery (including Gamma Knife and CyberKnife treatments). Amethyst Radioterapia Italy represents one regional center within this larger European network. The company operates on a partnership model with healthcare professionals and institutions, providing personalized, multidisciplinary cancer care treatments tailored to individual patient needs.

Differentiator

Problem solved

Functional benefit

Products and services

• Amethyst Radioterapia Italia (Italian Treatment Centre Network) Italian regional cancer care centre operated by Amethyst Healthcare Group, providing radiotherapy, brachytherapy, chemotherapy, and other oncology treatments to cancer patients in Italy through partnerships with public hospitals including Azienda Ospedaliera Regionale San Carlo in Potenza and Fatebenefratelli Hospital in Rome.
• External Beam Radiotherapy (LINAC-based VMAT/IMRT) External beam radiotherapy service using Elekta linear accelerators with advanced Volumetric Modulated Arc Therapy (VMAT) and Intensity-Modulated Radiation Therapy (IMRT) techniques for precise tumour targeting with millimetre accuracy; offered to cancer patients across the European network including Italy.
• Stereotactic Radiosurgery (Gamma Knife and CyberKnife) Non-invasive radiosurgery treatment using Leksell Gamma Knife (for intracranial conditions) and CyberKnife robotic systems (for intracranial and extracranial tumours) delivering millimetre-level precision radiation as an alternative to surgery; available at UK Gamma Knife centres in London and Sheffield, and Portugal's only dedicated CyberKnife system at Instituto CUF Porto.
• Institutional and Public-Private Partnerships Public-private partnership offering for hospitals, health authorities, and national health systems seeking to develop or expand oncology services; delivers sustainable investment, modern equipment, capacity increases, and clinical expertise under management contracts (illustrated by the partnership with Azienda Ospedaliera Regionale San Carlo in Potenza).
• Medical Practice Partnership Programme Partnership programme for physicians and cancer centre directors who wish to grow their practice while preserving clinical independence; offers long-term investments, access to the European specialist network, financial resources for equipment modernisation, succession planning, and strategic growth support.

Quantifiable outcome

• Approximately 35,000 radiotherapy treatments delivered annually across the European network
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

16 partnerships are on record, tiered major, minor and core.

• American Hospital of Paris (AHP)majorStrategic or Co-development Partner · 16 June 2026In June 2026, Stingray Healthcare Group announced a new strategic partnership with the American Hospital of Paris (AHP), under which it will assume operations of the Porte de Saint-Cloud Oncology Centre, improving access to innovative oncology treatments for AHP patients.
• Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC, Paris)majorStrategic or Co-development Partner · 10 June 2026Stingray Healthcare Group, through its French operations Amethyst, acquired the Porte de Saint-Cloud Oncology Centre in Paris as part of a strategic partnership, strengthening the group's presence in the Paris region.
• Global Coalition for RadiotherapyminorStrategic or Co-development Partner · 29 April 2026Stingray Healthcare Group announced a strategic partnership with the Global Coalition for Radiotherapy to advance the role of radiotherapy in global cancer care and improve awareness and access.
• Stingray Healthcare GroupcoreStrategic or Co-development Partner · 2 November 2025In November 2025, Amethyst Healthcare announced a strategic combination with Stingray Healthcare to create Europe's largest independent cancer care platform. The transaction followed Fremman Capital's acquisition of Stingray from Jacobs Capital. The combined entity operates 30+ treatment centres across 8 countries, delivering approximately 35,000 radiotherapy treatments annually. Ralph Hefti (founding CEO of Stingray) became CEO of the enlarged group. Both organisations maintain their local identities.
• Júlio TeixeiracoreStrategic or Co-development Partner · 6 October 2025Amethyst Healthcare acquired Júlio Teixeira, a well-established provider of radiotherapy services operating in Porto and Braga, Portugal. This acquisition established Amethyst's presence in the Portuguese market and strengthened the Group's Western European footprint.
• IASO-Health GmbHminorStrategic or Co-development Partner · 16 July 2025Amethyst Austria entered a partnership with IASO-Health GmbH, a Swiss-based integrative medicine provider led by CEO and Founder Bruno Rosset. This collaboration strengthens cross-border oncology pathways, giving IASO-Health patients direct access to cutting-edge radiotherapy treatments at Amethyst Vienna.
• Wiener Privatklinik (WPK)coreStrategic or Co-development Partner · 10 November 2020Amethyst Austria operates within Vienna's Wiener Privatklinik, Austria's largest private hospital. The partnership combines clinical expertise, cutting-edge technologies, and personalised care. WPK celebrated its 30th anniversary in 2025.
• Medical Equipment Solutions Limited (MESL)coreStrategic or Co-development Partner · 7 March 2020Amethyst Radiotherapy expanded into the UK through the acquisition of 100% of the share capital of Medical Equipment Solutions Limited (MESL), a specialised provider of intracranial radiation treatments using the Gamma Knife platform at Queen Square Radiosurgery Centre in London and Thornbury Radiosurgery Centre in Sheffield.
• Fatebenefratelli Order (San Giovanni Calibita Hospital, Rome)coreStrategic or Co-development Partner · 15 May 2017Amethyst opened its Rome centre in May 2017 through a partnership with the Fatebenefratelli order, which has operated the San Giovanni Calibita Hospital on Isola Tiberina. The centre provides radiotherapy services to patients in Rome and surrounding regions.
• Azienda Ospedaliera Regionale San Carlo (Potenza)coreStrategic or Co-development PartnerIn Italy, Stingray Healthcare Group has a presence in Potenza at the Azienda Ospedaliera Regionale San Carlo, the leading hospital in Basilicata. This partnership illustrates the Group's commitment to developing long-term collaborations with top healthcare institutions to enhance access to excellent cancer care.
• Medical University of ViennaminorStrategic or Co-development PartnerThe Vienna centre benefits from close collaboration with the Medical University of Vienna, combining clinical expertise and cutting-edge technologies to offer Austrian and international patients the highest standards of cancer care.
• Ludwik Rydygier Specialist Hospital (Krakow)coreStrategic or Co-development PartnerThe Krakow centre operates through a close partnership with Ludwik Rydygier Specialist Hospital, treating nearly 3,000 patients annually with radiotherapy, brachytherapy, and medical oncology. Treatment decisions are made collaboratively during multidisciplinary team meetings.
• National Hospital for Neurology and Neurosurgery (UCLH, London)coreStrategic or Co-development PartnerThe UK Gamma Knife centre in London is located at the National Hospital for Neurology and Neurosurgery (UCLH) and collaborates closely with Great Ormond Street Hospital, one of Europe's leading paediatric hospitals, for complex intracranial radiosurgery.
• Royal Hallamshire Hospital (Sheffield)coreStrategic or Co-development PartnerThe Sheffield Gamma Knife centre partners with the National Centre for Stereotactic Radiosurgery at Royal Hallamshire Hospital, providing patients access to internationally renowned expertise and the most advanced radiosurgery technologies.
• Instituto CUF PortocoreStrategic or Co-development PartnerIn Porto, Portugal, the centre is located within Instituto CUF Porto, equipped with Portugal's only dedicated CyberKnife system for precise treatment of intracranial and extracranial tumours.
• Hospital de BragacoreStrategic or Co-development PartnerIn Braga, Portugal, Stingray collaborates closely with the Braga Public Hospital to offer coordinated care based on clinical expertise, innovation, and complementarity between the public and private sectors.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• HCA Healthcare: Largest private hospital operator in the US with extensive oncology service lines including radiotherapy. Comparable as a global healthcare services incumbent, though primarily US-focused; relevant for capital allocation and oncology capacity benchmarking.
• Elekta: Global leader in linear accelerators (Versa HD), Gamma Knife and brachytherapy systems — a primary equipment supplier to the Amethyst network and a broader incumbent whose installed base shapes competitive radiotherapy capacity in Europe.
• Ramsay Health Care: Australia/UK/France-headquartered private hospital group operating cancer and radiotherapy services in markets overlapping with Amethyst (UK, France). Comparable as a multi-country private hospital incumbent with oncology service lines.
• Varian Medical Systems (Siemens Healthineers): Manufacturer of TrueBeam/Eclipse radiotherapy systems and the Halcyon LINAC, integrated within Siemens Healthineers. Indirect competitor through its installed-base strategy and oncology workflow software used across many European cancer centres competing with Amethyst.
• Fresenius Helios: Germany's largest private hospital operator (part of Fresenius SE) with extensive inpatient oncology, including radiotherapy centres. A broad incumbent that competes for PPP contracts and is one of the few pan-European hospital platforms at comparable scale.

Direct peers

• Affidea: European outpatient imaging and radiotherapy network operating across 15+ countries. Closely comparable to Amethyst on multi-country footprint, LINAC-based cancer services, and PPP model with public hospitals in markets such as Italy, Spain, Portugal and Central Europe.
• GenesisCare: Largest private cancer care services operator globally (also PE-backed), offering radiotherapy, medical oncology and theranostics across the US, UK, Spain and Australia. Directly comparable as a multi-country independent oncology platform competing for similar institutional PPPs and private-pay patients.

Emerging players

• ViewRay: US-listed developer of MR-guided radiation therapy systems (MRIdian). An emerging technology peer whose MR-linac innovation could either complement or compete with Amethyst's existing Elekta/Gamma Knife/CyberKnife stack over time.
• IBA (Ion Beam Applications): Belgian proton therapy and radiopharma equipment manufacturer with growing services footprint. Comparable as an emerging precision-radiotherapy player whose technology trajectory and proton/FLASH investments shape the long-term competitive landscape.

Regional players

• Spire Healthcare: UK private hospital operator providing oncology and radiotherapy services that overlap with Amethyst's UK Gamma Knife footprint. Regionally comparable rather than a direct multi-country competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amethyst-radioterapia-italia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMETHYST RADIOTERAPIA ITALIA